Sponsor Check › Person
Related person on Form D filings · address states as listed: NJ, MA, CA, NY · listed Apr 13, 2009 → Oct 13, 2015
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
1 of 21 offerings reports sales commissions totalling $1,012,000; 1 reports finder's fees totalling $4,739; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 28, 2019 D File 021-343084 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2015 D File 021-249197 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 14, 2015 D File 021-239899 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 25, 2015 D File 021-236650 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 24, 2015 D File 021-234589 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 23, 2014 D File 021-216080 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 3, 2013 D File 021-195932 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 3, 2013 D File 021-189318 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 6, 2012 D File 021-174381 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 23, 2012 D File 021-173852 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 12, 2011 D File 021-169899 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 7, 2011 D/A File 021-114428 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 15, 2011 D File 021-165882 | $1,012,000 | $4,739 | $0 | Leerink Swann LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Jul 14, 2011 D File 021-162866 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 18, 2011 D File 021-156981 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 20, 2010 D File 021-152213 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 23, 2010 D File 021-148095 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 2, 2010 D/A File 021-130159 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 30, 2009 D File 021-90990 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 4, 2009 D File 021-67751 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 21, 2009 D File 021-70770 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Ajax Therapeutics, Inc. | Director | Jun 28, 2019 | D | $8,000,000 similar: $500,000–$7,000,000 | $8,000,000 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Nora Therapeutics, Inc. | Director | Oct 13, 2015 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Nora Therapeutics, Inc. | Director | May 14, 2015 | D | $536,709 similar: $2,000,000–$19,999,994 | $0 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Mar 25, 2015 | D | $105,999,996 similar: $2,000,000–$19,999,994 | $105,999,996 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Feb 24, 2015 | D | $60,000,000 similar: $2,000,000–$19,999,994 | $20,710,000 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Nora Therapeutics, Inc. | Director | Apr 23, 2014 | D | $18,000,000 similar: $2,000,000–$19,999,994 | $18,000,000 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | May 3, 2013 | D | $50,000,001 similar: $2,000,000–$19,999,994 | $13,485,015 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ALVINE PHARMACEUTICALS INC | Director | Jan 3, 2013 | D | $6,506,500 similar: $829,831–$9,999,998 | $6,006,000 | 7 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Mar 6, 2012 | D | $17,110,000 similar: $2,000,000–$19,999,994 | $16,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SATORI PHARMACEUTICALS INC | Director | Feb 23, 2012 | D | $19,200,000 similar: $1,694,259–$16,000,000 | $15,000,000 | 0 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Dec 12, 2011 | D | $4,350,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Nov 7, 2011 | D/A | $55,664,000 similar: $2,000,000–$19,999,994 | $55,389,000 | 28 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Nov 3, 2011 | D/A | $55,664,000 similar: $2,000,000–$19,999,994 | $38,459,340 | 28 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KYTHERA BIOPHARMACEUTICALS INC | Director | Sep 15, 2011 | D | $52,424,997 similar: $1,694,259–$16,000,000 | $37,424,989 | 20 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Jul 14, 2011 | D | $6,000,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Mar 18, 2011 | D | $4,500,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 10 similar: 2–16 | $6,916 similar: $10,000–$50,000 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Dec 20, 2010 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 10 similar: 2–16 | $11,526 similar: $10,000–$50,000 |
| EDGAR ↗ | Nora Therapeutics, Inc. | Director | Sep 23, 2010 | D | $32,554,999 similar: $2,000,000–$19,999,994 | $14,880,000 | 5 similar: 2–16 | $12,950 similar: $10,000–$50,000 |
| EDGAR ↗ | Nora Therapeutics, Inc. | Director | Jun 2, 2010 | D/A | $25,137,000 similar: $2,000,000–$19,999,994 | $2,932,000 | 4 similar: 2–16 | $919 similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | May 3, 2010 | D/A | $55,664,000 similar: $2,000,000–$19,999,994 | $21,529,670 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Apr 5, 2010 | D | $51,139,000 similar: $2,000,000–$19,999,994 | $17,029,670 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Dec 22, 2009 | D/A | $26,550,000 similar: $2,000,000–$19,999,994 | $26,550,000 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Dec 10, 2009 | D/A | $26,550,000 similar: $2,000,000–$19,999,994 | $24,530,431 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | NGM BIOPHARMACEUTICALS INC | Director | Nov 13, 2009 | D/A | $26,550,000 similar: $2,000,000–$19,999,994 | $17,616,665 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Oct 30, 2009 | D | $49,940,274 similar: $2,000,000–$19,999,994 | $37,940,274 | 10 similar: 2–16 | $87,302 similar: $10,000–$50,000 |
| EDGAR ↗ | Trubion Pharmaceuticals, Inc | Director | Sep 4, 2009 | D | $10,000,000 similar: $2,000,000–$19,999,994 | $10,000,000 | 1 similar: 2–16 | $10,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Aug 21, 2009 | D | $28,881,642 similar: $2,000,000–$19,999,994 | $20,324,914 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Aug 12, 2009 | D | $500,000 similar: $2,000,000–$19,999,994 | $500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Jul 17, 2009 | D | $500,000 similar: $2,000,000–$19,999,994 | $500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | LUX BIOSCIENCES INC | Director | Jun 16, 2009 | D | $9,200,000 similar: $2,000,000–$19,999,994 | $9,200,000 | 10 similar: 2–16 | $21,167 similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Jun 10, 2009 | D | $1,500,000 similar: $2,000,000–$19,999,994 | $1,500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | May 6, 2009 | D | $1,700,000 similar: $2,000,000–$19,999,994 | $1,700,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Nora Therapeutics, Inc. | Director | Apr 13, 2009 | D | $24,000,000 similar: $2,000,000–$19,999,994 | $1,000,000 | 4 similar: 2–16 | $16,291 similar: $10,000–$50,000 |
| EDGAR ↗ | Gloucester Pharmaceuticals Inc | Director | Apr 10, 2009 | D | $1,500,000 similar: $2,000,000–$19,999,994 | $1,500,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); Biotechnology / 506(b) (3,253 filings); Other Health Care / 506(b) (4,189 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as David Schnell. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when David Schnell appears on a new Form D, or when a court case or SEC action is matched to them. See plans →